# Tanezumab In Osteoarthritis Of The Hip Or Knee

> **NCT00985621** · PHASE3 · TERMINATED · sponsor: **Pfizer** · enrollment: 614 (actual)

## Conditions studied

- Osteoarthritis

## Interventions

- **BIOLOGICAL:** tanezumab 10 mg
- **BIOLOGICAL:** tanezumab 5 mg
- **DRUG:** oxycodone
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT00985621
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-10-30
- **Primary completion:** 2010-12-13
- **Final completion:** 2011-02-04
- **Target enrollment:** 614 (ACTUAL)
- **Why stopped:** See termination reason in detailed description.
- **Last updated:** 2021-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00985621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00985621, "Tanezumab In Osteoarthritis Of The Hip Or Knee". Retrieved via AI Analytics 2026-09-13 from https://api.ai-analytics.org/clinical/NCT00985621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*